Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year

Galluzzo, Marco;Talamonti, Marina;Bernardini, Nicoletta;Chiricozzi, Andrea;De Simone, Clara;Bonifati, Claudio;Bruni, Pierluigi;Diotallevi, Federico;Esposito, Maria;Graceffa, Dario;Hansel, Katharina;Loconsole, Francesco;Moretta, Gaia;Mugheddu, Cristina

Member of the Collaboration Group

;Papini, Manuela;Richetta, Antonio;Skroza, Nevena;Atzori, Laura

Co-prime

Writing - Review & Editing

;Fargnoli, Maria Concetta;Persechino, Severino;Offidani, Annamaria;Stingeni, Luca;Peris, Ketty;Potenza, Concetta;Bianchi, Luca

2022-01-01

---

Abstract

Background: Real-world data on guselkumab, especially at times >6 months, are limited. Research design and methods: We performed a longitudinal, retrospective analysis on 307 patients with moderate–severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months. Main outcome measures: PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. Results: At 12 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 56.4%, 33.6%, and 24.1% of patients, respectively. At 52 weeks, PASI 75, PASI 90, and PASI 100 were achieved in 82.7%, 68.7%, and 51.1% of patients, respectively. Patients without comorbidities and those naïve to previous biological therapy had better responses. The mean Dermatology Life Quality Index score decreased from 14.0 at baseline to 3.1 at 12 weeks and 1.6 at 6 months, which was maintained at later times. Similar improvements were seen in pruritus visual analog scale. Conclusions: Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate–severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.